BACKGROUND: Malignant gliomas remain refractory to treatment despite advances in chemotherapy and surgical techniques. Viral vectors developed to treat gliomas have had low transduction capabilities, limiting their use. Gliomas over-express CD46, CD80, and CD86, all of which bind adenovirus serotype 3. METHODS: To increase the infectivity and replication of oncolytic vectors in malignant brain tumors, we created a conditionally replicating adenovirus, CRAd-Survivin-5/3, which contains a survivin promoter-driving E1A and a chimeric fiber consisting of adenovirus serotype 3 knob. RESULTS: In vitro, this modified CRAd showed ten- to 100-fold increased cytotoxicity against glioma cells. Ex vivo analysis of primary glioblastoma multiforme samples infected with CRAd-Survivin-5/3 showed an increase in cytotoxicity of 20-30% compared to adenovirus wild-type (AdWT). In normal human astrocytes and normal brain tissues, CRAd-Survivin-5/3 exhibited 30-40% and 10-15% lower cytotoxicity than AdWT, respectively. In an intracranial xenograft model of glioma, this oncolytic virus increased tumor-free survival and overall lifespan by 50% compared to controls (p < 0.05). CONCLUSIONS: CRAd-Survivin-5/3 represents an attractive alternative to existing vectors and should be tested further in the pre-clinical setting.
BACKGROUND:Malignant gliomas remain refractory to treatment despite advances in chemotherapy and surgical techniques. Viral vectors developed to treat gliomas have had low transduction capabilities, limiting their use. Gliomas over-express CD46, CD80, and CD86, all of which bind adenovirus serotype 3. METHODS: To increase the infectivity and replication of oncolytic vectors in malignant brain tumors, we created a conditionally replicating adenovirus, CRAd-Survivin-5/3, which contains a survivin promoter-driving E1A and a chimeric fiber consisting of adenovirus serotype 3 knob. RESULTS: In vitro, this modified CRAd showed ten- to 100-fold increased cytotoxicity against glioma cells. Ex vivo analysis of primary glioblastoma multiforme samples infected with CRAd-Survivin-5/3 showed an increase in cytotoxicity of 20-30% compared to adenovirus wild-type (AdWT). In normal human astrocytes and normal brain tissues, CRAd-Survivin-5/3 exhibited 30-40% and 10-15% lower cytotoxicity than AdWT, respectively. In an intracranial xenograft model of glioma, this oncolytic virus increased tumor-free survival and overall lifespan by 50% compared to controls (p < 0.05). CONCLUSIONS: CRAd-Survivin-5/3 represents an attractive alternative to existing vectors and should be tested further in the pre-clinical setting.
Authors: A Temme; E Herzig; B Weigle; A Morgenroth; M Schmitz; A Kiessling; M A Rieger; H K Schackert; E P Rieber Journal: Hum Gene Ther Date: 2005-02 Impact factor: 5.695
Authors: E Antonio Chiocca; Khalid M Abbed; Stephen Tatter; David N Louis; Fred H Hochberg; Fred Barker; Jean Kracher; Stuart A Grossman; Joy D Fisher; Kathryn Carson; Mark Rosenblum; Tom Mikkelsen; Jeff Olson; James Markert; Steven Rosenfeld; L Burt Nabors; Steven Brem; Surasak Phuphanich; Scott Freeman; Rick Kaplan; James Zwiebel Journal: Mol Ther Date: 2004-11 Impact factor: 11.454
Authors: J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza Journal: Gene Ther Date: 2000-05 Impact factor: 5.250
Authors: Yaman Tekant; Julia Davydova; Pedro J Ramirez; David T Curiel; Selwyn M Vickers; Masato Yamamoto Journal: Surgery Date: 2005-05 Impact factor: 3.982
Authors: Winan J Van Houdt; Yosef S Haviv; Baogen Lu; Minghui Wang; Angel A Rivera; Ilya V Ulasov; Martine L M Lamfers; Daniel Rein; Maciej S Lesniak; Gene P Siegal; Clemens M F Dirven; David T Curiel; Zeng B Zhu Journal: J Neurosurg Date: 2006-04 Impact factor: 5.115
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Sanne K van den Hengel; Jeroen de Vrij; Taco G Uil; Martine L Lamfers; Peter Ae Sillevis Smitt; Rob C Hoeben Journal: Virol J Date: 2011-04-11 Impact factor: 4.099
Authors: Lynda Coughlan; Raul Alba; Alan L Parker; Angela C Bradshaw; Iain A McNeish; Stuart A Nicklin; Andrew H Baker Journal: Viruses Date: 2010-10-13 Impact factor: 5.818